Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expanded US Approval Set To Take Janssen’s Darzalex Higher

Executive Summary

Janssen’s multiple myeloma therapy, Darzalex, has won an additional US approval for use earlier in the treatment paradigm, building momentum for a product that has already got off to a strong start.

Advertisement

Related Content

Keeping Track: Approvals For Xultophy, Soliqua And Darzalex; NDAs From Intarcia And GSK; Complete Response For Green Cross
J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches
Accelerated EU Committee Nod for J&J/Genmab's Darzalex
BMS/AbbVie Empliciti Leaps Ahead, Wins Fast FDA Nod
Janssen/Genmab Win 1st Anti-CD38 In Multiple Myeloma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097720

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel